Paediatric HIV update

Journal of Paediatrics and Child Health

Volumn 33, Issue 5, 1997, Pages 373-377

  Ziegler, J B ^a   Palasanthiran, P ^b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b NONE

Author keywords

Diagnosis; HIV; Infants and children; Perinatal transmission; Prevention

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

AUSTRALIA; BOTTLE FEEDING; CESAREAN SECTION; DRUG MIXTURE; FETUS MEMBRANE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION CONTROL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

EID: 0030728905     PISSN: 10344810     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1754.1997.tb01623.x     Document Type: Review

References (35)

1. Quinn TC. Global burden of the HIV pandemic. [Review], Lancet 1996; 348: 99-106.
2. World Health Organization. AIDS. In Point of Fact 1995; 86: 1-2.
3. National Centre in HIV Epidemiology and Clinical Research. Australian HIV Surveillance Report 1995; 11: 14-29.
4. McDonald AM, Cruikshank M, Ziegler JB et al. Perinatal exposure to HIV in Australia, 1982-1994. Med. J. Aust. 1997; 166: 77-80.
5. Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992; 340: 585-8.
6. Connor EM, Sperling RS, Gelber R et al. Reduction of maternalinfant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. 1994; 331: 1173-80.
7. Sperling RS, Shapiro DE, Coombs RW et al. Maternal viral load, zidovudine treatment and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. W. Engl. J. Med. 1996; 339: 1621-9.
8. Elford J, MacDonald MA, Gabb RG et al. Antenatal HIV antibody testing in Australia. Med. J. Aust. 1995; 163: 183-5.
9. Bryson YJ, Luzuriaga K, Wara DW. Proposed definition for in utero versus intrapartum transmission of HIV-1. N. Engl. J. Med. 1993; 327: 1246-7.
10. Rouzioux C, Costagliola O, Burgard M et al. Timing of mother-to-child transmission depends on maternal status. AIDS 1993; 7 (Suppl 2): S49-52.
11. Owens DK, Holodniy M, McDonald TW et al. A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in infants. JAMA 1996; 275: 1342-8.
12. Bryson YJ, Pang S, Wei MS et al. Clearance of HIV infection in a perinatally infected infant. N. Engl. J. Med. 1995; 332: 833-8.
13. Roques PA, Gras G, Parnet-Mathieu F et al. Clearance of HIV infection in 12 perinatally infected children: virological and immunological data. AIDS 1995; 9: F19-26.
14. Newell ML, Dunn D, De Maria A et al. Detection of virus in vertically exposed HIV-antibody-negative children. Lancet 1996; 347: 213-5.
15. Bakshi SS, Tetali S, Abrams EJ et al. Repeatedly positive human immunodeficiency virus type 1 DNA polymerase chain reaction in human immunodeficiency virus-exposed seroreverting infants. Pediatr. Infect. Dis. J. 1995; 14: 658-62.
16. Palasanthiran P, Ziegler JB, Dwyer DE et al. Early detection of human immunodeficiency virus infection in Australian infants at risk of infection and factors affecting transmission. Pediatr. Infect. Dis. J. 1994; 13: 1083-90.
17. Blanche S, Mayaux M, Rouzioux C et al. Relation of the course of HIV infection in children to the severity of the disease in their mothers at delivery. N. Engl. J. Med. 1994; 330: 308-12.
18. European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. Lancet 1992; 339: 1007-12.
19. St Louis ME, Kamenga M, Brown C et al. Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic, and placental factors. JAMA 1993; 269: 2853-9.
20. Mayaux MJ, Blance S, Rouxioux C et al. Maternal factors associated with perinatal HIV-1 transmission: the French Cohort Study: 7 years of follow-up observation. The French Pediatric HIV Infection Study Group. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 1995; 8: 188-94.
21. Dickover RE, Garratty EM, Herman SA et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. JAMA 1996; 275: 599-605.
22. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood, France, United Kingdom, and United States, January 1988-August 1994. MMWR 1995; 44: 929-33.
23. Landesman SH, Kalish LA, Burns DN et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. N. Engl. J. Med. 1996; 334: 1617-23.
24. Auger I, Thomas P, De Gruttola V et al. Incubation periods for paediatric AIDS patients. Nature 1988; 3336: 575-7.
25. Blanche S, Tardieu M, Duliege AM. A longitudinal study of ninety-four symptomatic infants with perinatally acquired human immunodeficiency virus infection: evidence for bimodal expression of clinical and biological symptoms. Am. J. Dis. Child. 1990; 144: 1210-5.
26. Tovo PA, De Martino M, Gabiano C et al. Prognostic factors and survival in children with perinatal HIV-1 infection. Lancet 1992; 339: 1249-53.
27. Anonymous. Features of children perinatally infected with HIV-1 surviving longer than 5 years. Italian Register for HIV Infection in Children. Lancet 1994; 343: 191-5.
28. Newell M, Loveday C, Dunn D et al. The use of PCR and quantitative antibody tests in children born to HIV-1 infected mothers. J. Med. Virol. 1995; 47: 330-5.
29. Anonymous. Report of a consensus workshop, Siena, Italy, January 17-18, 1992. Early diagnosis of HIV intection in infante. J. Acqu. Immune Def. Synd. 1992; 5: 1169-78.
30. Paul MO, Tetali S, Lesser ML et al. Laboratory diagnosis of infection status in infants perinatally exposed to human immunodeficiency virus type 1. J. Infect. Dis. 1996; 173: 68-76.
31. CDC. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with the human immunodeficiency virus. MMWR 1991; 40 (RR-2): 1-13.
32. European Collaborative Study Group. CD4 T cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIV. BMJ 1994; 308: 437-40.
33. Anonymous. 1995; revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. MMWR 1995; 44 (RR-4): 1-11.
34. Englund, JA, Baker, W, Raskin, C et al. Zidovudine, didanosine or both as initial treatment for symptomatic HIV-infected children. N. Engl. J. Med. 1997; 336: 1704-12.
35. McClernon DR, Vavro C, Valentine M, St. Clair M, McKinney RE, Jr. The effect of combination lamivudine-zidovudine (3TC-ZDV) therapy in antiretroviral therapy experienced children. Washington: 1997; 4th National Conference on Retroviruses, Jan 22-26, 1997. (Abstract)